Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome (FertIL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03578497
Recruitment Status : Recruiting
First Posted : July 6, 2018
Last Update Posted : May 13, 2020
Sponsor:
Information provided by (Responsible Party):
University Hospital, Basel, Switzerland

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A prospective, interventional, open-label, single-arm, proof-of-concept study: 18 women with Polycystic Ovary Syndrome (PCOS) will be treated with 100 mg of Anakinra/Kineret® for 4 weeks. 1 week after last injection patients will have a follow-up and a dexamethasone visit after a dexamethasone suppression test. Goal of this study is to investigate the effect of the Interleukin 1( IL-1) receptor antagonist Anakinra/Kineret® on laboratory and clinical features in women with PCOS.

Condition or disease Intervention/treatment Phase
Polycystic Ovary Syndrome Drug: IL-1 receptor antagonist Anakinra Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome - a Prospective, Interventional, Single-arm, Open-label, Proof-of-concept Study
Actual Study Start Date : August 31, 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Anakinra

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: IL-1 receptor antagonist Anakinra 100 mg
Anakinra (Kineret®; r-metHuIL-1ra, Swedish Orphan Biovitrum AB) is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Anakinra/Kineret® is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colorless-to-white, preservative free solution for daily s.c. administration over a time period of 28 days.
 Drug: IL-1 receptor antagonist Anakinra
IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
Other Name: Kineret


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Absolute change in fasting serum androstenedione level (nmol/l) from start (baseline, day 1) to one week after treatment start with Anakinra. [ Time Frame: 7 days ]
    Absolute change in fasting serum androstenedione level (nmol/l) from start (baseline, day 1) to one week after treatment start with Anakinra.


Secondary Outcome Measures :
  1. Ferriman-Gallwey-score [ Time Frame: Day 1 and 28 ]
    Effect of Anakinra/Kineret® on hirsutism by Ferriman-Gallwey-score (representation of hair growth in a male pattern on a woman shown in four different degrees of severity ( 0= no hair growth; 1= light hair growth; 2= moderate hair growth; 4= severe hair growth) in 11 different body parts; namely the upper lip, chin, chest, upper back, lower back, upper abdomen, lower abdomen, arm, forearm, thigh, and lower leg) will be assessed

  2. Sebum production measures [ Time Frame: At day 1 and 28 ]
    Effect of Anakinra/Kineret® on sebum production will be assessed with Sebumeter® SM 815, Courage + Khazaka electronic Gesellschaft mit beschränkter Haftung (GmbH)

  3. Self-reported frequency of hair removal (times/week) [ Time Frame: At day 1 and 28 ]
    Effect of Anakinra/Kineret® on hirsutism will be assessed

  4. Plewig-Kligman-score [ Time Frame: At day 1 and 28 ]
    Effect of Anakinra/Kineret® on acne severity, assessed with Plewig-Kligman score (presentation of comedonal and inflammatory acne severity, separately graded based on the number of lesions and type; lesion counting done at right side of the face, excluding other side, chest and back.

  5. Ovulation and menstruation rates [%] [ Time Frame: Between day 1 and day 35 ]
    Effect of Anakinra/Kineret® on ovulation and menstruation rates will be assessed

  6. Estradiol (pmol/l), free testosterone (nmol/l), total testosterone (nmol/l), sex hormone-binding globulin (SHBG) [nmol/l], Anti-Muellerian Hormone [pmol/l], dehydroepiandrosterone (DHEA) [nmol/l]), basal cortisol (nmol/l) [ Time Frame: Day 1, 7, 14, 21, 28 and 35 ]
    Effect of Anakinra/Kineret® on peripheral (sexual) hormones will be assessed

  7. Fasting glucose (mmol/l), homeostatic model of assessment of insulin resistance (HOMA-IR) [ Time Frame: At day 1, 7, 14, 21, 28 and 35 ]
    Effect of Anakinra/Kineret® on glucose metabolism will be assessed

  8. Pituitary hormones (luteinizing hormone (LH), follicle stimulating hormone (FSH), adrenocorticotropic hormone (ACTH) [IU/L]) [ Time Frame: Day 1, 7, 14, 21, 28 and 35 ]
    Effect of Anakinra/Kineret® on the pituitary-gonadal axis will be assessed

  9. Treatment response according to a Dexamethasone suppression test [ Time Frame: At days 35 and 36 ]
    Dexamethasone suppression test will be evaluated as a predictor for treatment response

  10. inflammatory marker white blood cell count [x109/l], [ Time Frame: Day 1, 7, 14, 21, 28 and 35 ]
    Time course of inflammatory marker white blood cell count [x109/l] will be assessed

  11. inflammatory marker C reactive protein (CRP) [mg/l] [ Time Frame: Day 1, 7, 14, 21, 28 and 35 ]
    Time course of inflammatory marker CRP [mg/l] will be assessed

  12. inflammatory marker IL-6 [pg/ml] [ Time Frame: Day 1 and 28 ]
    Time course of inflammatory marker IL-6 [pg/ml] will be assessed

  13. inflammatory marker IL-1Ra [pg/ml] [ Time Frame: Day 1, 7, 14, 21, 28 and 35 ]
    Time course of inflammatory marker IL-1Ra [pg/ml] will be assessed

  14. Change in androstenedione level (nmol/l) from start (baseline, day 1) to days 14, 21, 28, and 35 after treatment start with Anakinra. [ Time Frame: Days 14, 21, 28, and 35 after treatment start with Anakinra ]
    Change in androstenedione level (nmol/l) from start (baseline, day 1) to days 14, 21, 28, and 35 after treatment start with Anakinra.

  15. Change in 11-oxygenated androgens (e.g. 11-ketotestosterone, 11-ketoandrostenedione, 11β-hydroxytestosterone, 11β-hydroxyandrostenedione [nmol/l]) on days 7, 14, 28, and 35 after treatment start with Anakinra [ Time Frame: Days 7, 14, 28, and 35 after treatment start with Anakinra ]
    Change in 11-oxygenated androgens (e.g. 11-ketotestosterone, 11-ketoandrostenedione, 11β-hydroxytestosterone, 11β-hydroxyandrostenedione [nmol/l]) on days 7, 14, 28, and 35 after treatment start with Anakinra


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Informed Consent as documented by signature
  • Premenopausal women aged 18 years or older
  • Onset of menarche ≥5 years ago
  • Diagnosis of PCOS defined by the Rotterdam criteria
  • High sensitivity C-reactive protein level ≥1 mg/l

  • Follicular phase of menstrual cycle as evident by

    • Serum estradiol level <200 pmol/l AND
    • Serum progesterone level <8 ng/ml
  • Willingness to use non-hormonal contraceptive measures adequate to prevent becoming pregnant during the study

Exclusion Criteria:

  • Intake of any testosterone level modifying drugs in the 8 weeks prior to study inclusion,
  • Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to Anakinra/Kineret,
  • Women who are pregnant or breast feeding,
  • Female participants who are ovariectomized or hysterectomised or post-menopausal
  • Known or suspected non-compliance, drug or alcohol abuse,
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
  • Participation in another study with investigational drug within the 30 days preceding and during the present study,
  • Previous enrolment into the current study,
  • Enrolment of the investigator, his/her family members, employees and other dependent persons,
  • Clinical signs of infection in the week before inclusion or history of a severe infection during the last 2 months,
  • Potentially severe immunosuppression or intake of other immunosuppressive drugs
  • Severe hematologic disease
  • Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, active carcinoma),
  • History of or suspected tuberculosis and/or hepatitis B/C
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03578497


Contacts
Layout table for location contacts
Contact: Mirjam Christ-Crain, Prof. Dr. MD +41 61 265 48 96 mirjam.christ-crain@usb.ch
Contact: Milica Popovic +41 61 328 56 92 milica.popovic@usb.ch

Locations
Layout table for location information
Switzerland
University Hospital Basel Endocrinology, Diabetes and Metabolism Recruiting
Basel, Switzerland, 4031
Contact: Mirjam Christ-Crain, Prof.Dr. MD    +41 61 265 48 96    mirjam.christ-crain@usb.ch   
Contact: Milica Popovic       milica.popovic@usb.ch   
Sub-Investigator: Gideon Sartorius, PD Dr.med         
Sub-Investigator: Marc Donath, Prof. Dr.med         
Sub-Investigator: Fahim Ebrahimi, Dr. med         
Sub-Investigator: Wiebke Arlt, Prof. Dr. med         
Sponsors and Collaborators
University Hospital, Basel, Switzerland
Investigators
Layout table for investigator information
Principal Investigator: Mirjam Christ-Crain, Prof. Dr. MD University Hospital Basel, Dep. of Endocrinology, Diabetes and Metabolism
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT03578497    
Other Study ID Numbers: 2018-00780; me16CC6
First Posted: July 6, 2018    Key Record Dates
Last Update Posted: May 13, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by University Hospital, Basel, Switzerland:
Interleukin-1 receptor antagonism
Kineret/Anakinra
testosteron
hyperandrogenemia
androstenedione
Additional relevant MeSH terms:
Layout table for MeSH terms
Polycystic Ovary Syndrome
Syndrome
Disease
Pathologic Processes
Ovarian Cysts
Cysts
Neoplasms
 Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents